Table 2 Clinical studies to increase Treg frequency and function in different neurodegenerative disorders
From: Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders
Clinical Phase | Intervention | Condition | Status | Trial identifier | Outcome |
|---|---|---|---|---|---|
I & II | Autologous Treg (GB301) | AD | Not yet recruiting | – | |
II | Sargramostim (rhGM-CSF) | AD | Completed | Improved memory function [181] | |
– | Dimethyl fumarate (Tecfidera) | MS | Approved | Approved as first line monotherapy | |
– | Fingolimod (FTY720) | MS | Approved | First orally approved therapy | |
II | Low dose IL-2 | MS | Recruiting | – | |
NA | Vitamin D3 | MS | Completed | Unaffected Tregs [228] | |
II (WIRMS) | Hookworm larvae | MS | Completed | – | |
I | Sargramostim (rhGM-CSF) | PD | Completed | Improved motor function [24] | |
I | Sargramostim (rhGM-CSF) | PD | Active | – | |
I | Autologous Treg with IL-2 | ALS | Completed | Slow disease progression [225] | |
II | Autologous Treg with IL-2 | ALS | Recruiting | – | |
II (MIROCALS) | Riluzole with IL2 and 5% glucose water solution | ALS | Recruiting | – | |
II (TEALS) | Dimethyl fumarate (Tecfidera) | ALS | Not yet recruiting | ACTRN12618000534280 | – |